Radiopharm Theranostics reports 93% MRI concordance

Radiopharm Theranostics reported in RAD101 Phase 2b a 93% concordance between PET and MRI in 30 evaluable patients with suspected brain metastases, along with preliminary 86% sensitivity; the company plans a U.S. Phase 3 pivotal trial in Q4 2026 as it advances toward a registrational program. In RAD204 Phase 1, Patient 1 achieved a durable partial response with up to 43% tumor reduction and progression-free status beyond seven months, while Patient 2 shows early signs of anti-tumor activity and remains on treatment.